HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Limitations of anticoagulant therapy].

Abstract
Vitamin K antagonists have been shown to be effective in the primary and secondary prevention of systemic and cerebral emboli in patients with cardiac causes of embolism, especially atrial fibrillation. The reduced risk of stroke is greater in secondary prevention, although this reduction is accompanied by an inherent risk of hemorrhagic complications, among which cerebral hemorrhage is especially serious. The therapeutic window of these agents is limited and the best benefit/risk profile is obtained with an INR of between 2 and 3. The anticoagulant effect obtained shows marked variability, requiring frequent clinical and laboratory monitoring of the treatment. The introduction of oral anticoagulants that would aid the administration of these agents with equal or greater efficacy and lower risk is required.
AuthorsJ Martí-Fàbregas, R Delgado-Mederos, J Mateo
JournalNeurologia (Barcelona, Spain) (Neurologia) Vol. 27 Suppl 1 Pg. 27-32 (Mar 2012) ISSN: 1578-1968 [Electronic] Spain
Vernacular TitleLimitaciones del tratamiento anticoagulante.
PMID22682207 (Publication Type: English Abstract, Journal Article, Review)
CopyrightCopyright © 2012 Sociedad Española de Neurología. Published by Elsevier Espana. All rights reserved.
Chemical References
  • Anticoagulants
  • Fibrinolytic Agents
  • Vitamin K
Topics
  • Anticoagulants (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Atrial Fibrillation (complications)
  • Blood Coagulation (drug effects)
  • Drug Monitoring
  • Fibrinolytic Agents (adverse effects, therapeutic use)
  • Heart Diseases (complications)
  • Humans
  • International Normalized Ratio
  • Intracranial Embolism (etiology, prevention & control)
  • Primary Prevention
  • Risk
  • Secondary Prevention
  • Stroke (etiology, prevention & control)
  • Thrombophilia (drug therapy, etiology)
  • Vitamin K (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: